Burgeoning Drug Discovery Activities to Spur Demand for Cell Based Assays

Cell-based assay is fast gaining traction in understanding cellular mechanisms in the pharmaceutical and biotechnology industry in a biological context. Cell-based assays are widely preferred for performing high-throughput screenings (HTS) world over. They are extensively used for a variety of applications, including toxicity studies, discovering intracellular molecular targets, and custom bioassays to study drug stability and potency. In recent years, combining these methods with fluorescence technologies has furthered its applications. They play a significant role in various drug discovery approaches adopted by pharmaceutical companies. 

The widening prevalence of chronic diseases, the growing number of drug discovery screening methods in several emerging economies, and recent advances in assay chemistries are key factors expected to bolster the demand for cell-based assays. In addition, the growing demand for stem cell assays for discovering new oncology drugs and biologics, coupled with spiraling government expenditure on discovering novel therapies, is expected to accentuate the market. 

With numerous exciting applications emerging in biotechnology, according to Transparency Market Research (TMR), the market for cell-based assays is anticipated to reach a valuation of US$19,710.7 mn by the end of 2022; the market stood at US$13,576.7 mn in 2017.

Which product types are expected to witness major demand across end-use applications?

The major product types used in cell-based assays comprise reagents and consumables, assay kits, services, software, and instruments. Of these, reagents and consumables witnessed substantial demand for performing cell-based assays by pharmaceutical and biotech companies. The segment accounted for the major share and stood at US$4,356.6 mn in 2017, attributed to a substantial uptake among prominent biopharmaceutical companies in developing and developed regions. Furthermore, the growing use of reagents in drug discovery screening methods in measuring cell viability, cytotoxicity, and apoptosis is boosting the growth of the segment. The rising prominence of contract research organizations is a key trend anticipated to accentuate the demand for reagents and consumables. According to TMR, the segment is projected to rise at a CAGR of 7.5% during the forecast period. 

In recent years, there have been several tie-ups and collaborations, especially in developed regions. LumaCyte, a prominent biotech company based Charlottesville, VA., announced in September, 2017 that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership, essentially focused on developing robust manufacturing  capabilities for existing and emerging biopharmaceutical products. The organization is sponsored by an agency of the United States Department of Commerce. The Laser Force Cytology (LFC) technology developed by LumaCyte will enable biopharmaceutical players to achieve a rapid and automated cell-based assays combined with HTS, across the U.S., believes the company. 

Which regions are predicted to offer lucrative avenues for market players?

The major regions contributing to the revenue of cell-based assays market are divided into Europe, North America, Asia Pacific except Japan (APEJ), Latin America, and the Middle East and Africa (MEA), and Japan. Among these, North America is witnessing the dominant demand for cell-based assays, with the demand being US$5,164.0 million in 2017. The region is projected to be most lucrative market for cell-based assays and is predicted to lead throughout the forecast period. The substantial uptake is expected to be fueled by burgeoning spending on biomedical research in major countries, especially the U.S. Robust drug discovery screening activities in various parts of the region is likely to bolster the uptake of reagents and consumables among biopharmaceutical companies. The regional market for cell-based assays is expected to be worth US$7,672.5 million by the end of 2022.

Meanwhile, APEJ is projected to rise at a substantial pace registering CAGR of 8.1% vis-à-vis during the forecast period. Countries such as China and India are predicted to witness wide demand for researches in bioassay developments. 


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports